Dade and Sysmex extend alliance to 2004:
This article was originally published in Clinica
Dade Behring and Sysmex have extending their marketing alliance for haemostasis products to June 2004. Under the exclusive, global agreement, the companies supply a single source for analysers and reagents to measure patients' ability to form and dissolve blood clots. The new contract can automatically be renewed for two-year periods if both companies agree.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.